Emilie Kaczmarek

Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial

Alexander Olawaiye, Laurence Gladieff, David M. O’Malley et al. · The Lancet · 2025 · 46 citations

Medicine, Oncology, Pharmacology +13

Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)

Nicholas C. Turner, Cristina Saura, Philippe Aftimos et al. · Journal of Clinical Oncology · 2024 · 32 citations · Full text

Medicine, Oncology, Pharmacology +17

386MO Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: Final results of the phase III TULIP trial

Philippe Aftimos, Nicholas C. Turner, Joyce O’Shaughnessy et al. · Annals of Oncology · 2023 · 18 citations · Full text

Medicine, Oncology, Breast Oncology +16

Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database

Emilie Kaczmarek, C. Saint-Martin, J-Y Pierga et al. · Breast Cancer Research and Treatment · 2019 · 10 citations

Medicine, Oncology, Pharmacotherapy +17